Lasting response after discontinuation of cemiplimab in a patient with locally advanced basal cell carcinoma

Clin Exp Dermatol. 2021 Dec;46(8):1612-1614. doi: 10.1111/ced.14804. Epub 2021 Jul 29.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Carcinoma, Basal Cell / drug therapy*
  • Carcinoma, Basal Cell / pathology
  • Ear Auricle / pathology
  • Ear Neoplasms / drug therapy*
  • Ear Neoplasms / pathology
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Male
  • Skin / pathology
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology

Substances

  • Antibodies, Monoclonal, Humanized
  • Immune Checkpoint Inhibitors
  • cemiplimab